CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 8 enrolled
Drug / intervention
Bosentandrug
Likely dose
Bosentan 62.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01721564
NCT01721564N/ACompleted
CompareCT.gov

Pulmonary Artery Remodelling With Bosentan

Prof David S Celermajer·interventional·Posted Nov 5, 2012·Updated Oct 19, 2016

In Brief

A clinical study evaluating Bosentan for Pulmonary Arterial Hypertension. Completed, enrolled 8 participants.

Detailed Summary

6 months therapy of Bosentan, an endothelin antagonist, will lead to improvement in pulmonary microvascular endothelial function.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Arterial Hypertension
Countries--
Collaborators--

Timeline

N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 5, 2012
Enrollment StartApr 1, 2006
Primary CompletionMay 1, 2009
Study CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 13.7 years ago

Interventions

Bosentandrug

62.5 mg Bosentan twice a day for 1 month 125 mg Bosentan twice a day for 5 months